Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

NCT02678741 is registered in ClinicalTrials.gov with Elios Therapeutics, LLC as lead sponsor.

NCT NCT02678741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02678741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.
Lead sponsor
Elios Therapeutics, LLC
Phase
Phase 1/2
Overall status
Completed
Start date
February 29, 2016
Completion date
November 13, 2019
Enrollment
26 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma